Search
Powered By HealthLine
Special Offers
Health Tools
 Neurology Health Center
 Understanding Multiple Sclerosis
 Fibromyalgia Basics
 Video: Alzheimer's Disease
 Migraine - What is it?
Featured Conditions
 Alzheimer's
 Chronic Pain
 Multiple Sclerosis
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Celebrex, Naproxen Won't Prevent Mental Decline

New findings suggest daily use of naproxen might even harm cognitive function

By Amanda Gardner
HealthDay Reporter


Related Encyclopedia
 border=
Acoustic Neurinoma
Alzheimer's Disease
Bell's Palsy
Brain and Spinal Cord Magnetic Resonance Imaging
More...

Related Healthscout Videos
 border=
The On-X Valve PROACT Trial
The On-X Heart Valve: Longevity With Less Reliance on Coumadin
Tissue Valves vs. Mechanical Valves
What is the difference between heart valve repair and replacement?
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Erectile Dysfunction
What is a Heart Attack?
More...

Related Drug Information
 border=
Actonel
Adderal XR
Concerta
Coumadin
More...

Related News Articles
 border=
Work Strife Stresses the Heart
Abnormal Heartbeat After Bypass a Bad Sign
Lowered HRT Use May Have Cut Heart Attacks
With Peripheral Artery Disease, Med Adherence Is Low
More...

MONDAY, May 12 (HealthDay News) -- Contrary to prior studies, a new trial shows that daily use of two popular pain-relieving drugs, Celebrex and naproxen, does not prevent cognitive decline in people with a family history of Alzheimer's disease.

In fact, naproxen, which goes under the brand names Aleve and Naprosyn, may even have a deleterious effect on cognitive function, the study found.

Text Continues Below



"The drugs we studied did not seem to improve cognitive function and, if anything, there was some weak evidence for a detrimental effect," said Barbara Martin, an investigator on the trial and assistant professor of epidemiology at the Johns Hopkins School of Public Health in Baltimore. "So we don't at this time recommend taking NSAIDs for the purpose of preventing Alzheimer's or cognitive decline."

Added Dr. John Morris, director of the Alzheimer's Disease Research Center at Washington University School of Medicine in St. Louis and a member of the medical and scientific advisory council for the Alzheimer's Association: "My strong recommendation is I would not take any drug for a hoped-for effect until it has been demonstrated to have such an effect. Drugs potentially have side effects and unless there's a documented benefit, just because it's popular, I wouldn't rush to do that."

Both Celebrex and naproxen belong to the class of pain-killing drugs known as non-steroidal anti-inflammatory drugs (NSAIDs).

The study, to be published in the July issue of Archives of Neurology, was funded by the U.S. National Institute on Aging. The drug maker Pfizer provided the supply of Celebrex used in the study, plus a matching placebo, while Bayer Healthcare provided naproxen and a matching placebo.

Inflammatory processes may play a role in Alzheimer's disease and in cognitive decline in general.

"In addition to the plaques and tangles which are pathological hallmarks of Alzheimer's, there also seem to be signs of inflammation in the brains of people with the disease," Martin said.

Page:  1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 5/12/2008

Related Links
 border=
From Healthscout's partner site on chronic pain, ChronicPainConnection.com
Find ways to get chronic pain relief!
Find a right treatment for your chronic pain
Join our community - your chronic pain support group.





SOURCES: Barbara K. Martin, Ph.D., assistant professor, epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore; John Morris, M.D., professor, neurology and director, Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis and member, medical and scientific advisory council, Alzheimer's Association; Gary J. Kennedy, M.D., director, geriatric psychiatry, Montefiore Medical Center, New York City; July 2008, Archives of Neurology


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map